Triple negative breast cancer is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study was to explore the clinical relevance of Lehmann triple negative breast cancer subtypes by identifying any differences in response to neoadjuvant chemotherapy among them.
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
Specimen part, Treatment
View Samples